Molnupiravir

Paxlovid and molnupiravir are the go-to treatments for non-hospitalized patients, replacing nearly all the monoclonal antibody infusions, which are less effective against current COVID strains.

New York City COVID infections have been on the rise once again in recent weeks, and while there’s no corresponding increase in severity, the health commissioner is reminding the public and providers that antiviral pills are effective treatments, too. Paxlovid, specifically, can reduce the risk of hospitalization and death by up to 88% when taken within five days of symptoms…

NYC is raising its COVID alert level as the number of new cases rises. It is a new alert system put into effect earlier in 2022, and for now it has been raised to medium, which won’t yet bring new restrictions, but that could change if it goes higher. NBC New York’s Andrew Siff reports.

The Food and Drug Administration approved an emergency use authorization for the first oral antiviral treatment of COVID-19.

U.S. health advisers have endorsed an antiviral drug from Merck to treat COVID-19.

Britain has granted a conditional authorization to Merck’s coronavirus antiviral

Drugmaker Merck has asked U.S. regulators to authorize its promising antiviral pill against COVID-19, setting the stage for a decision within weeks